J9145
J9145 – Injection, daratumumab, 10 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 2 NDCs crosswalked per 10 MG $73.770/unit ASP+6%
📋 J9145 summary
J9145 is a HCPCS Level II J-code used to bill daratumumab, 10 mg, billed per 10 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J9145: Darzalex, Darzalex Iv
Code J9145
Billing unit 10 MG Payment limit $73.770/unit NDC-Crosswalk 2
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ9145
DescriptorInjection, daratumumab, 10 mg
Billing unit10 MG
Payment limit / unit$73.770
Est. ASP / unit$69.594 est.
Mapped NDCs2
Data periodQ3 2026
Last updated2026-08-20
💊 About Daratumumab Injection DRUG GUIDE
Darzalex is approved for adult patients with multiple myeloma.
It can be used in newly diagnosed patients who are not candidates for a stem cell transplant, in newly diagnosed patients who are eligible for a stem cell transplant (when used with certain combination regimens), and in patients whose myeloma has returned or stopped responding to earlier treatments.Depending on how far the disease has progressed and which medicines a patient has tried before, Darzalex may be given alone or combined with other drugs such as lenalidomide, bortezomib, thalidomide, carfilzomib, pomalidomide, melphalan, and dexamethasone.
Each combination has its own specific set of criteria — your oncologist will determine which regimen fits your situation.
Clinical overview from our editorial drug guide for Daratumumab Injection. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$73.770
Est. ASP / unit
$69.594 est.
Est. after 2% sequester
$72.295
HCPCS dosage
10 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, daratumumab, 10 mg
CoverageD — Special coverage instructions apply
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1D
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2017-01-01
Date added2017-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J9145 = 10 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J9145 WITH EST. MEDICARE PAY
2 NDCs map to J9145. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($73.770/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 57894-0505-05 | Darzalex IV Daratumumab 100 mg/5mL INJECTION, SOLUTION, CONCENTRATE | Janssen | 1 VIAL, SINGLE-DOSE in 1 BOX (57894-505-05... | 100 mg/5mL | 10 | $737.70 | — | ● Active | CMS ASP |
| 57894-0505-20 | Darzalex IV Daratumumab 100 mg/5mL INJECTION, SOLUTION, CONCENTRATE | Janssen | 1 VIAL, SINGLE-DOSE in 1 BOX (57894-505-20... | 100 mg/5mL | 40 | $2,950.80 | — | ● Active | CMS ASP |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$22.67M
Claims
2,647
Beneficiaries
920
Spend / beneficiary
$24,642.58
Spend / claim
$8,564.86
Trend by period
Where J9145 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #119 of 824
#114
PANZYGA J1576
$23.9M
#115
MVASI Q5107
$23.53M
#116
SAPHNELO J0491
$23.21M
#117
REMODULIN* J3285
$22.85M
#118
ANKTIVA J9028
$22.83M
#119
DARZALEX J9145
$22.67M
#120
ONIVYDE J9205
$22.24M
#121
EPKINLY J9321
$21.11M
#122
SARCLISA J9227
$21.08M
#123
XIAFLEX J0775
$20.97M
#124
HYQVIA J1575
$20.77M
Total claims — #282 of 824
#277
CALCIUM GLUCONATE-NA... J0612
2,730
#278
ELAHERE J9063
2,700
#279
BORUZU J9054
2,691
#280
DYSPORT J0586
2,683
#281
IDOSE TR J7355
2,681
#282
DARZALEX J9145
2,647
#283
KRYSTEXXA J2507
2,633
#284
EOVIST A9581
2,602
#285
COMPLETE FT PER SQ C... Q4271
2,572
#286
REMODULIN* J3285
2,534
#287
SKYRIZI J2327
2,523
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $22.67M | 920 | 2,647 | $24,642.58 | $8,564.86 |
| 2025 (Q1-Q4) | $111.4M | 1,586 | 13,565 | $70,237.68 | $8,212.09 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$65.57M
Medicare paid
$50.82M
Submitted services
1,043,016
Denial rate
7.2%
Allowed / service
$67.76
Submitted charges
$163.71M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J9145 is utilized CMS · BY PROVIDER · 2024
Medicare Part B services for this code by the rendering provider's state — 106,512 services across 5 states & territories in 2024 (CMS reports include DC and U.S. territories). Switch to per 100k to compare states fairly regardless of population. Hover or tap a state for its top ZIP codes.
Hover or tap a state to see its numbers + top ZIP codes.
Per-capita = services ÷ 2023 state population × 100,000 (so high-population states aren't automatically "hotter"). Counts reflect the provider's location, not the patient's. Providers with fewer than 11 patients are hidden by CMS for privacy, so totals run low and per-100k can be noisy in small states — read this as relative geography, not exact counts. Source: CMS Medicare Physician & Other Practitioners — by Provider and Service, 2024.
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
2 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J9145 billing FAQ
What is HCPCS code J9145?
J9145 is a HCPCS Level II J-code used to bill Injection, daratumumab, 10 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9145?
One unit of J9145 represents 10 MG. Report the number of units equal to the dose administered divided by 10 MG.
How many units of J9145 should I bill?
Divide the dose administered by the code's unit size (10 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9145?
The Medicare Part B payment limit is $73.770 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $72.295 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9145?
2 NDCs currently map to J9145 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9145 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.